Votrient

(Pazopanib)

Phase 3Small molecule

Pazopanib is used to treat certain types of cancer, including advanced kidney cancer and soft tissue sarcoma. It works by blocking proteins that help cancer cells grow and form new blood vessels.[1] Votrient is currently being investigated across 68 indications[3], with its most advanced program in Phase 3.[1]

Votrient is one of 1139 small molecule programs targeting Fibrosarcoma. It is currently in Phase 3.

Indications

240

Total Trials

Active Trials

1,138

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

FibrosarcomaActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

ParagangliomaActive, not recruiting

Salivary Gland CancerActive, not recruiting

LeiomyosarcomaActive, not recruiting

Kidney CancerActive, not recruiting

Corneal NeovascularizationActive, not recruiting

Lung CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

FibrosarcomaPhase 2

Active, not recruiting

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Corneal NeovascularizationPhase 1

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Showing 10 of 67 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Votrient

Novartis

Phase 3

8 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Kidney Cancer

NCT01684397

Q4 2026

Phase 2/3Active, not recruiting

Soft Tissue Sarcoma

NCT02180867

Phase 2Recruiting

Rhabdomyosarcoma

NCT06816771

Q1 2027

Phase 2/3Active, not recruiting

Uterine Leiomyosarcoma

NCT05432791

Q2 2027

Phase 2Recruiting

Treatment

NCT06739395

Clinical

Trials by Indication[1]

Renal Cell Carcinoma18 trials

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00731211·57 enrolled

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Completed·TTechnical University of Munich·Phase 3·NCT01613846·544 enrolled

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 1/2·NCT01513187·53 enrolled

Show 15 more trials

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Terminated· Novartis logo

Novartis·Phase 2·NCT01545817·74 enrolled

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Completed· Novartis logo

Novartis·Phase 2·NCT03200717·62 enrolled

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

Completed· GSK logo

GSK·Phase 1·NCT00992121·11 enrolled

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01392183·69 enrolled

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01472081·194 enrolled

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT02959554·49 enrolled

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT01147822·367 enrolled

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis··NCT01649778·662 enrolled

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Completed·IInstitut Claudius Regaud·Phase 4·NCT02555748·47 enrolled

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01361113·21 enrolled

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Completed·IiOMEDICO AG·Phase 4·NCT01521715·44 enrolled

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Completed·—·Phase 1·NCT02406521·30 enrolled

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Recruiting·XXynomic Pharmaceuticals, Inc.·Phase 3·NCT03592472·413 enrolled

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 3·NCT00720941·1,110 enrolled

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5

Completed·CCancer Trials Ireland·Phase 2·NCT01566747·43 enrolled

Soft Tissue Sarcoma15 trials

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01418001·5 enrolled

Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib

Terminated·GGWT-TUD GmbH·Phase 4·NCT03735758·11 enrolled

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed·UUniversity of Washington·N/A·NCT01446809·23 enrolled

Show 12 more trials

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Terminated·UUniversity of Washington·Phase 1/2·NCT03660930·19 enrolled

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Completed· GSK logo

GSK·Phase 3·NCT00753688·369 enrolled

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT01532687·54 enrolled

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Completed·WWashington University School of Medicine·Phase 2·NCT02300545·56 enrolled

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT02180867·140 enrolled

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Active, not recruiting·IIntensity Therapeutics, Inc.·Phase 3·NCT06263231·333 enrolled

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Completed· GSK logo

GSK·Phase 2·NCT00297258·148 enrolled

A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

Completed·HHannover Medical School·Phase 2·NCT01861951·120 enrolled

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Withdrawn·NNYU Langone Health·Phase 2·NCT03149120

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Completed·UUniversity of Vermont·Phase 1/2·NCT01719302·6 enrolled

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Withdrawn· GSK logo

GSK·Phase 2·NCT02367651

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07444619·18 enrolled

Kidney Cancer9 trials

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT01684397·51 enrolled

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Terminated·—·Phase 2·NCT03334409·5 enrolled

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01664182·41 enrolled

Show 6 more trials

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Completed·—·Phase 2·NCT01158521·25 enrolled

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Completed·—·Phase 2·NCT01157091·28 enrolled

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Completed·MMayo Clinic·Phase 2·NCT01767636·38 enrolled

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

Terminated·UUniversity of Chicago·N/A·NCT01599832·20 enrolled

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT02960906·200 enrolled

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Terminated·VVirginia Commonwealth University·Phase 1·NCT02795819·6 enrolled

Breast Cancer8 trials

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00509587·21 enrolled

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00450879·19 enrolled

Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 1·NCT01498458·9 enrolled

Show 5 more trials

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Terminated·UUniversity of Arizona·Phase 2·NCT01394211·2 enrolled

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00849472·101 enrolled

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00558103·163 enrolled

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Completed·—·Phase 2·NCT01466972·30 enrolled

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00347919·189 enrolled

Non-Small Cell Lung Cancer7 trials

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Terminated· GSK logo

GSK·Phase 2·NCT01313663·20 enrolled

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT01208064·102 enrolled

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Completed· GSK logo

GSK·Phase 2·NCT00871403·107 enrolled

Show 4 more trials

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Withdrawn·LLoyola University·Phase 2·NCT01179269

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

Completed· GSK logo

GSK·Phase 2·NCT00367679·35 enrolled

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Completed· GSK logo

GSK·Phase 1·NCT00866528·30 enrolled

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Terminated· GSK logo

GSK·Phase 2·NCT00549328·14 enrolled

91 more indications

Ovarian Cancer6 trials

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Completed·IImperial College London·Phase 1·NCT01608009·16 enrolled

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Unknown status·JJSehouli·Phase 1/2·NCT01600573·68 enrolled

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Terminated·TThe Christie NHS Foundation Trust·Phase 1/2·NCT02055690·21 enrolled

Show 3 more trials

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Completed·PPriv.-Doz. Dr. med. Joachim Rom·Phase 1/2·NCT01238770·10 enrolled

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT01262014·28 enrolled

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Completed·LLinda R Duska·Phase 2·NCT01610206·148 enrolled

Refractory Solid Tumors6 trials

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Unknown status·SSamsung Medical Center·Phase 1/2·NCT03628131·46 enrolled

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01552356·54 enrolled

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Completed·SSamsung Medical Center·N/A·NCT02691767·2 enrolled

Show 3 more trials

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Recruiting·TTianjin Medical University Second Hospital·Phase 1/2·NCT06895733·65 enrolled

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT01130623

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Completed·SSamsung Medical Center·N/A·NCT02450136·2 enrolled

Patients With Advanced Solid Tumors4 trials

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Withdrawn·SSWOG Cancer Research Network·Phase 1·NCT00788580

GW786034 in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00060151

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting·CCentre Leon Berard·Phase 2·NCT02029001·900 enrolled

Show 1 more trial

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors

Completed·UUNICANCER·Phase 1·NCT01165385·35 enrolled

Small Cell Lung Cancer4 trials

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

Completed·HHellenic Oncology Research Group·Phase 2·NCT01713296·58 enrolled

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Completed·—·Phase 2·NCT01253369·33 enrolled

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Terminated·NNorthwestern University·Phase 1·NCT01060514·8 enrolled

Show 1 more trial

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Terminated·IIllinois CancerCare, P.C.·Phase 2·NCT01049776·32 enrolled

Thyroid Cancer3 trials

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Completed·UUniversity of Washington·Phase 1·NCT01413113·6 enrolled

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00625846·152 enrolled

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01236547·123 enrolled

Patients With Solid Tumors3 trials

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00929903·55 enrolled

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT01639911·28 enrolled

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00516672·30 enrolled

Treatment3 trials

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06739395·300 enrolled

Combined Modality Treatment of Sarcomas of the Extremities

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT01985295·12 enrolled

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Unknown status·CCentre Leon Berard·Phase 3·NCT04741438·96 enrolled

Advanced Solid Tumors3 trials

Pazopanib and ARQ 197 for Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01468922·32 enrolled

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00678977·22 enrolled

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00722293·111 enrolled

Gastrointestinal Stromal Tumor3 trials

Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Completed·SScandinavian Sarcoma Group·Phase 2·NCT01524848·72 enrolled

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Withdrawn·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02342600

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Terminated·KKristen Ganjoo·Phase 2·NCT01391611·25 enrolled

Solid Tumors2 trials

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Completed· Novartis logo

Novartis·Phase 2·NCT01956669·57 enrolled

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01454804·43 enrolled

Age-Related Macular Degeneration2 trials

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Completed· GSK logo

GSK·Phase 2·NCT01134055·510 enrolled

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Terminated· GSK logo

GSK·Phase 2·NCT01362348·19 enrolled

Melanoma2 trials

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Completed·UUniversity of California, Irvine·Phase 2·NCT01107665·60 enrolled

Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel

Completed·UUniversity of Zurich·Phase 2·NCT01666418·19 enrolled

Gemcitabine2 trials

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Completed·UUNICANCER·Phase 2·NCT01442662·106 enrolled

Pazopanib Vs. Pazopanib Plus Gemcitabine

Active, not recruiting·NNorth Eastern German Society of Gynaecological Oncology·Phase 2·NCT02203760·58 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT01377298·45 enrolled

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·WWashington University School of Medicine·Phase 1·NCT01716416·32 enrolled

Angiosarcoma2 trials

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Completed·FFox Chase Cancer Center·Phase 2·NCT01462630·29 enrolled

Evaluation of Votrient in Angiosarcoma

Terminated·HHeidelberg University·Phase 2·NCT02212015·26 enrolled

Glioblastoma2 trials

Pazopanib in Treating Patients With Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00459381·35 enrolled

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Withdrawn·CCenter Trials & Treatment·Phase 1·NCT03275558

Urothelial Cancer2 trials

Pazopanib and Vinflunine in Urothelial Cancer of the Bladder

Completed·PProf. Dr. Thomas Otto·Phase 1/2·NCT01265940·5 enrolled

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Completed·SSandy Srinivas·Phase 2·NCT01108055·43 enrolled

Prostate Cancer2 trials

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00486642·23 enrolled

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454571·37 enrolled

Primary Peritoneal Cancer2 trials

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00866697·940 enrolled

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

Completed· GSK logo

GSK·Phase 2·NCT01227928·145 enrolled

Hereditary Hemorrhagic Telangiectasia2 trials

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Unknown status·CCure HHT·Phase 1/2·NCT03850730·30 enrolled

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Active, not recruiting·CCure HHT·Phase 2/3·NCT03850964·70 enrolled

Relapsed or Refractory2 trials

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT03139331·16 enrolled

Metastatic Sarcoma2 trials

Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients

Terminated·TThe Netherlands Cancer Institute·Phase 2·NCT02575066·25 enrolled

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT02601209·151 enrolled

Liposarcoma2 trials

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Completed·VVector Oncology·Phase 2·NCT01506596·42 enrolled

Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT01692496·52 enrolled

Advanced Solid Malignancies2 trials

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Terminated·NNew Mexico Cancer Research Alliance·Phase 1·NCT01542047·3 enrolled

Cervical Cancer2 trials

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02348398

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Completed· GSK logo

GSK·Phase 2·NCT00430781·228 enrolled

Cancer2 trials

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Unknown status·UUniversity Medical Center Groningen·Phase 4·NCT05949424·30 enrolled

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

Completed· GSK logo

GSK·Phase 1·NCT00363194·28 enrolled

Glioblastoma Multiforme2 trials

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Recruiting·CCentre Antoine Lacassagne·Phase 1/2·NCT02331498·51 enrolled

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01931098·35 enrolled

Uterine Leiomyosarcoma2 trials

Pazopanib for Treating Uterine Leiomyosarcoma

Withdrawn·GGynecologic Oncology Group·Phase 2·NCT02378142

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT05432791·73 enrolled

Recurrent1 trial

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Completed·VVector Oncology·Phase 1·NCT00800345·33 enrolled

Metastatic Melanoma1 trial

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00861913·13 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Completed·NNorthwestern University·Phase 1/2·NCT01465659·29 enrolled

Fallopian Tube Cancer1 trial

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT01402271·88 enrolled

Neuroendocrine Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454363·52 enrolled

Renal Cell Cancer1 trial

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Withdrawn·—·N/A·NCT02307474

Single Dose1 trial

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

Completed· GSK logo

GSK·Phase 1·NCT00659555·24 enrolled

Paraganglioma1 trial

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01340794·7 enrolled

Uterine Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01247571·22 enrolled

Metastatic Urothelial Cancer1 trial

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00471536·19 enrolled

Nasopharyngeal Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454142·33 enrolled

Bladder Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01031875·41 enrolled

Bone Sarcoma1 trial

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Completed·NNorthwestern University·Phase 2·NCT02357810·178 enrolled

Malignant Pleural Mesothelioma1 trial

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00459862·34 enrolled

Advanced Malignant Tumors1 trial

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Completed·MManisha Shah·Phase 1·NCT01713972·23 enrolled

Second-line Treatment1 trial

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Unknown status·SSouthern China Urology Cancer Consortium·Phase 2·NCT02324803·86 enrolled

Elderly1 trial

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Completed· GSK logo

GSK·Phase 1·NCT00463320·29 enrolled

Fallopian Tube1 trial

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01468909·106 enrolled

Von Hippel-Lindau Syndrome1 trial

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01436227·32 enrolled

Tolerance1 trial

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors

Completed·IInstitut Bergonié·Phase 2·NCT01876082·72 enrolled

Metastatic Neuroendocrine Tumor1 trial

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Completed·SSamsung Medical Center·Phase 2·NCT01099540·37 enrolled

Gastric Cancer1 trial

Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer

Terminated·HHellenic Oncology Research Group·Phase 1/2·NCT01716546·51 enrolled

Neovascular AMD1 trial

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Completed· GSK logo

GSK·Phase 2·NCT00612456·70 enrolled

Rhabdomyosarcoma1 trial

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06816771·38 enrolled

Phase II1 trial

Pazopanib Maintenance Phase II

Terminated·LLudwig-Maximilians - University of Munich·Phase 2·NCT02207309·1 enrolled

ESS1 trial

Study To Assess Long Term Safety Of Pazopanib

Completed· Novartis logo

Novartis·Phase 1·NCT00387205·188 enrolled

Salivary Gland Carcinoma1 trial

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Completed·UUNICANCER·Phase 2·NCT02393820·72 enrolled

Alveolar Soft Part Sarcoma1 trial

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Terminated·SSeoul National University Hospital·Phase 2·NCT02113826·6 enrolled

Capecitabine1 trial

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Completed· GSK logo

GSK·Phase 1·NCT00387387·50 enrolled

SCLC1 trial

Pazopanib Maintenance for SCLC

Completed·SSamsung Medical Center·Phase 2·NCT01797874·97 enrolled

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01339871·152 enrolled

Bleeding1 trial

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

Terminated· GSK logo

GSK·Phase 2·NCT02204371·7 enrolled

Chondrosarcoma1 trial

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Completed·EEmerald Clinical Inc.·Phase 2·NCT01330966·47 enrolled

Frail Elderly Patients1 trial

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Terminated·IInstitut Claudius Regaud·Phase 1·NCT01642017·18 enrolled

Fibrosarcoma1 trial

Phase II Pazopanib Study in Advanced Dermatofibrosarcomas

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01059656·23 enrolled

Advanced Cancers1 trial

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00674024·8 enrolled

CRC1 trial

pazopanib_NCRCC,Ph2 STUDY

Completed·SSamsung Medical Center·Phase 2·NCT01538238·10 enrolled

Carboplatin1 trial

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Completed· GSK logo

GSK·Phase 1·NCT00388076·86 enrolled

Treatment Outcome1 trial

Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Completed·RRadboud University Medical Center··NCT01995981·22 enrolled

Prospective1 trial

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04462445·25 enrolled

Hypertension1 trial

HYPAZ: Hypertension Induced by Pazopanib

Terminated·—·Phase 2·NCT01392352·31 enrolled

Metastatic Renal Cell Cancer1 trial

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Completed· GSK logo

GSK·Phase 3·NCT00387764·80 enrolled

Adenocarcinoma1 trial

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Terminated·SSCRI Development Innovations, LLC·Phase 1/2·NCT01035658·22 enrolled

Advanced NSCLC1 trial

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Terminated·WWashington University School of Medicine·Phase 2·NCT02193152·16 enrolled

Resistance1 trial

Rotating Pazopanib and Everolimus to Avoid Resistance

Completed·NNetherlands Working Group on Immunotherapy of Oncology·Phase 2·NCT01408004·101 enrolled

Osteosarcoma1 trial

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

Terminated·EEmerald Clinical Inc.·Phase 2·NCT01759303·12 enrolled

Advanced1 trial

Pazopanib as Single Agent in Advanced NETs

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT01280201·44 enrolled

RCC1 trial

Optimizing Pazopanib Exposure in RCC Patients

Terminated·IInteressenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.·Phase 2·NCT02089802·6 enrolled

Pancreatic Cancer1 trial

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT01080248·2 enrolled

Efficacy and Safety1 trial

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Completed·SSpanish Oncology Genito-Urinary Group··NCT02282579·300 enrolled

Lymphedema1 trial

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Completed·KKathy Miller·Phase 2·NCT00827372·10 enrolled

Pembrolizumab1 trial

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Completed· Incyte logo

Incyte·Phase 3·NCT03260894·129 enrolled

Malignant Glioma1 trial

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Completed· GSK logo

GSK·Phase 2·NCT00350727·75 enrolled

Advanced Cancer1 trial

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01548144·178 enrolled

Chemotherapy1 trial

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Completed· GSK logo

GSK·Phase 2·NCT00561795·12 enrolled

Metastatic Prostate Cancer1 trial

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Terminated·IIllinois CancerCare, P.C.·Phase 2·NCT00945477·11 enrolled

Corneal Neovascularization1 trial

Treatment of Corneal Neovascularization With Topical Pazopanib

Completed·RReza Dana, MD·Phase 1/2·NCT01257750·20 enrolled

Penile Carcinoma1 trial

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Terminated·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT02279576·4 enrolled

Psoriasis1 trial

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Completed· GSK logo

GSK·Phase 1·NCT00358384·10 enrolled

Prostate1 trial

Pazopanib, Docetaxel, Prednisone Prostate

Completed·—·Phase 1·NCT01385228·36 enrolled

Unspecified8 trials

VEG111485: A QTc Study of Pazopanib

Completed· GSK logo

GSK·Phase 1·NCT00861029·2 enrolled

Pazopanib Tolerability When Given With Food

Completed·RRadboud University Medical Center·Phase 1·NCT02138526·78 enrolled

Hepatic Monitoring for Pazopanib

Completed· GSK logo

GSK··NCT01449825·1 enrolled

Show 5 more trials

An Extension to Study MD7108240

Completed· GSK logo

GSK·Phase 2·NCT00733304·42 enrolled

Dose Escalation Study of Pazopanib Plus TH-302

Completed·HHerbert Hurwitz, MD·Phase 1·NCT01485042·50 enrolled

A Study of Pazopanib With CAPEOX in AGC Patients

Completed·SSamsung Medical Center·Phase 2·NCT01130805·66 enrolled

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01430572·62 enrolled

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01072214·37 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 19, 2009

VOTRIENT

NDA NDA022465

Sources

References

[1]
ClinicalTrials.gov — 240 trial records for Pazopanib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pazopanib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pazopanib. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022465). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Macrophage Colony Stimulating Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase ITK/TSK Inhibitor; Tyrosine-Protein Kinase LCK Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Votrient

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Renal Cell Carcinoma18 trials

Soft Tissue Sarcoma15 trials

Kidney Cancer9 trials

Breast Cancer8 trials

Non-Small Cell Lung Cancer7 trials

Ovarian Cancer6 trials

Refractory Solid Tumors6 trials

Patients With Advanced Solid Tumors4 trials

Small Cell Lung Cancer4 trials

Thyroid Cancer3 trials

Patients With Solid Tumors3 trials

Treatment3 trials

Advanced Solid Tumors3 trials

Gastrointestinal Stromal Tumor3 trials

Solid Tumors2 trials

Age-Related Macular Degeneration2 trials

Melanoma2 trials

Gemcitabine2 trials

Head and Neck Squamous Cell Carcinoma2 trials

Angiosarcoma2 trials

Glioblastoma2 trials

Urothelial Cancer2 trials

Prostate Cancer2 trials

Primary Peritoneal Cancer2 trials

Hereditary Hemorrhagic Telangiectasia2 trials

Relapsed or Refractory2 trials

Metastatic Sarcoma2 trials

Liposarcoma2 trials

Advanced Solid Malignancies2 trials

Cervical Cancer2 trials

Cancer2 trials

Glioblastoma Multiforme2 trials

Uterine Leiomyosarcoma2 trials

Recurrent1 trial

Metastatic Melanoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

Fallopian Tube Cancer1 trial

Neuroendocrine Cancer1 trial

Renal Cell Cancer1 trial

Single Dose1 trial

Paraganglioma1 trial

Uterine Cancer1 trial

Metastatic Urothelial Cancer1 trial

Nasopharyngeal Cancer1 trial

Bladder Cancer1 trial

Bone Sarcoma1 trial

Malignant Pleural Mesothelioma1 trial

Advanced Malignant Tumors1 trial

Second-line Treatment1 trial

Elderly1 trial

Fallopian Tube1 trial

Von Hippel-Lindau Syndrome1 trial

Tolerance1 trial

Metastatic Neuroendocrine Tumor1 trial

Gastric Cancer1 trial

Neovascular AMD1 trial

Rhabdomyosarcoma1 trial

Phase II1 trial

ESS1 trial

Salivary Gland Carcinoma1 trial

Alveolar Soft Part Sarcoma1 trial

Capecitabine1 trial

SCLC1 trial

Germ Cell Tumor1 trial

Cholangiocarcinoma1 trial

Advanced Malignancies1 trial

Bleeding1 trial

Chondrosarcoma1 trial

Frail Elderly Patients1 trial

Fibrosarcoma1 trial

Advanced Cancers1 trial